Related Experiment Video
Updated: Sep 10, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
RNA drugs and nonviral nanocarriers in oncology - present status and emerging concepts
1Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, University of Leipzig. Germany.
Abstract:
RNA molecules offer attractive therapeutic strategies in oncology, based on mechanisms of action different to existing medications. The therapeutic application of RNAs, however, is still associated with major bottlenecks, including poor stability and pharmacokinetics. Non-viral nanoparticle formulations represent systems for RNA protection, delivery and cell internalization. They have to meet defined requirements for providing sufficient efficacy, specificity and biocompatibility. Moreover, the selection of the RNA drug as payload is of major relevance. As a result of intense research over the past decades, a wide variety of different RNA classes are available for interference with pathophysiological processes. This review provides an overview of various RNA classes as drug candidates, including RNAs mediating loss-of-function (siRNAs for gene knockdown, sgRNAs for gene knockout, gene- or base-editing), gain-of-function (mRNA, sa-mRNA, circRNA for ectopic overexpression) or modulation of gene expression (miRNAs, antimiRs or circRNAs for miRNA inhibition), among others. Dependent on the target organ, target cell and type of RNA molecule, different nanoparticle systems can provide efficient RNA formulations. New therapeutic strategies may also cover combinations of different types of RNAs, associated with different properties and thus requiring even more sophisticated nanocarriers for their delivery. The various classes of nanocarriers available for RNA formulation are reviewed and discussed as well. Beyond therapeutic in vivo application, RNA-based strategies may also be of relevance in cell-based therapies, for non-viral ex vivo modification of immune cells. While this would offer advantages over existing viral transduction strategies, it will also rely on sufficiently efficient non-viral systems for cell modification. Overall, nonviral systems for the delivery of RNA therapeutics are needed to fulfil the potential of these approaches in the clinic.
Insights
Non-viral nanoparticles are crucial for delivering RNA therapeutics in oncology, overcoming challenges like poor stability. These advanced systems protect RNA drugs, enhancing their efficacy and paving the way for new cancer treatments.
Area of Science:
- Biotechnology and Nanomedicine
- Oncology Therapeutics
- Molecular Biology
Background:
- RNA molecules present novel therapeutic avenues in oncology, distinct from conventional drugs.
- Key challenges for RNA therapeutics include poor stability and pharmacokinetics, limiting clinical application.
- Non-viral nanoparticle formulations are essential for protecting, delivering, and internalizing RNA payloads.
Purpose of the Study:
- To review various RNA classes as potential drug candidates for oncological applications.
- To discuss different non-viral nanoparticle systems for efficient RNA formulation and delivery.
- To explore the role of RNA therapeutics in both in vivo and ex vivo cell-based therapies.
Main Methods:
- Comprehensive review of RNA classes: small interfering RNAs (siRNAs), small guide RNAs (sgRNAs), messenger RNAs (mRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs).
- Analysis of diverse non-viral nanocarrier systems designed for RNA formulation.
- Evaluation of RNA therapeutic strategies for loss-of-function, gain-of-function, and gene expression modulation.
Main Results:
- Various RNA types (siRNA, mRNA, miRNA, etc.) offer diverse mechanisms for interfering with cancer pathways.
- Nanoparticle systems demonstrate potential for tailored RNA delivery based on target organ, cell, and RNA type.
- Non-viral systems are critical for ex vivo modification of immune cells, offering an alternative to viral methods.
Conclusions:
- Non-viral nanoparticle systems are indispensable for realizing the clinical potential of RNA therapeutics in oncology.
- Sophisticated nanocarriers are needed to deliver combination RNA therapies with diverse properties.
- Advancements in non-viral delivery systems are key to overcoming current limitations in RNA-based cancer treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Microorganisms in Medicine and Therapeutics

